Berkeley HeartLab adopts GenTegra DNA to support diagnostic genetic testing for cardiovascular disease

GenVault Corporation today announced that Berkeley HeartLab, a subsidiary of Celera Corporation (Nasdaq: CRA), has adopted GenTegra DNA to preserve and store diagnostic samples for genetic testing related to the management of cardiovascular disease.  

As new clinically important diagnostic genetic markers are introduced, such as KIF6 and LPA, accessing stored DNA eliminates the need to collect a new sample and facilitates return of potentially critical medical information back to the physician.  Currently, Berkeley HeartLab offers 39 individual clinical laboratory tests.

"GenVault is excited to partner with Berkeley HeartLab in the application of our GenTegra technology in support of diagnostic genetic testing," said David Wellis, Ph.D., President and CEO at GenVault.  "Berkeley HeartLab's extensive and successful validation of GenTegra within their CLIA-certified and CAP-accredited laboratory is testimony to the robustness and quality of GenVault's technologies in managing clinical samples."

"At Berkeley HeartLab, the further integration of genetic tests into the standard panels of cardiovascular diagnostics requires efficient, high quality DNA handling and management," said Jean Amos Wilson, Ph.D., Vice President of Laboratory Operations at Berkeley HeartLab. "GenVault's GenTegra DNA provides a robust infrastructure for supporting our genetic testing business."